“significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment”

Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms.

Results:

In both groups there was a significant reduction in the Kupperman index following 12 weeks
of treatment, which was sustained throughout the 12 months of treatment (p < 0.01).
Seventy-six percent of the patients in the SD group reported a decrease in vasomotor
symptoms and seventy-eight % in the LD group (NS). This decrease was sustained following
12 months of treatment. There was no change in TSH and sex hormone levels or endometrial
thickness during the study period.